Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms.

ABSTRACT:

Background

Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing's syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective. Patients unsuitable for bilateral adrenalectomy (BA) have dismal outcomes. Peptide receptor radionuclide therapy (PRRT) is a rational option for hormone and disease control in ECS caused by NEN with high somatostatin receptor (SSTR) expression.

Aim

To describe the characteristics and outcomes of patients with ECS treated with PRRT.

Methods

Single-centre, retrospective analysis of imaging, biochemistry and outcomes of seven consecutive patients with ECS caused by metastatic GEPNEN treated with PRRT from 2006 to 2023.

Results

Patients were aged 17-75 (female n 

SUBMITTER: Boehm E 

PROVIDER: S-EPMC11623253 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature